Mushroom Polysaccharides and Cancer: How They Fight Tumors

Mushroom Polysaccharides & Cancer

3 approved cancer drugs

Three polysaccharide compounds derived from medicinal mushrooms are approved for cancer treatment in Japan, each backed by meta-analyses showing improved survival versus chemotherapy alone.

Narayanan et al., Curr Oncol Rep, 2023

PSK

Turkey Tail polysaccharide — 40+ years of clinical use in Japan

Lentinan

Shiitake compound with documented benefit across 9 cancer types

2024

Year of the most recent meta-analysis confirming lentinan + chemo benefit

Narayanan et al., Curr Oncol Rep, 2023

View as image ↗

Japan approved the first mushroom-derived cancer drug in the 1980s. That was not a supplement industry decision; it was the result of clinical trials conducted by academic medical centers and government health agencies. The compound was PSK, a polysaccharide extracted from Turkey Tail mushroom. A 2023 systematic review by oncology researchers reviewed all published clinical studies on medicinal mushroom supplements in cancer and concluded that Turkey Tail and shiitake had the strongest clinical evidence of any mushroom species, specifically through their polysaccharide compounds.^[7]

Mushroom polysaccharides, primarily beta-glucans, fight cancer through two routes: indirectly by activating macrophages, NK cells, T cells, and dendritic cells to attack tumors, and directly by inducing apoptosis, arresting cell division, and cutting off tumor blood supply. The three most clinically developed are PSK, lentinan, and schizophyllan, all approved in Japan.

This article covers how those two mechanisms work, what the clinical evidence shows, and how to read the evidence honestly. For the full landscape of medicinal mushrooms in oncology, see the complete guide to medicinal mushrooms in cancer treatment.

What Mushroom Polysaccharides Are (and Why These Are Not Ordinary Supplements)

Polysaccharides are long chains of sugar molecules. The ones found in medicinal mushrooms are primarily beta-glucans, the structural carbohydrates that form fungal cell walls.

That classification matters. Beta-glucans are not vitamins, minerals, or alkaloids. They are molecular patterns that human immune cells have evolved specific receptors to detect. When a beta-glucan binds to one of those receptors, it triggers measurable biological responses. In the context of cancer, those responses have been developed into prescription drugs.

Maehara and colleagues' comprehensive 2012 review of PSK's mechanisms and decades of clinical use described PSK's distinctive molecular structure as enabling "dual immunostimulatory and direct antiproliferative activity": it activates immune cells against tumors while also directly inhibiting tumor cell growth.^[4]

Three mushroom polysaccharides have cleared the clinical evidence bar to become approved cancer drugs in Japan. PSK comes from Turkey Tail mushroom. Lentinan comes from shiitake. Schizophyllan comes from Schizophyllum commune. Each has a distinct molecular structure, different receptor targets, and a separate evidence base. None are FDA-approved in the United States.

Understanding what separates these three from general mushroom supplements is the starting point for reading anything in this field accurately.

Two Routes to Anti-Cancer Activity: Immune Activation and Direct Tumor Attack

The research on mushroom polysaccharides describes two fundamentally different ways they act against cancer.

The first is indirect. Polysaccharides bind to pattern recognition receptors on immune cells, triggering a cascade that activates the body's tumor-fighting cells. The tumor never encounters the polysaccharide directly; it encounters an immune system that the polysaccharide has put on high alert.

The second is direct. Polysaccharides can act on tumor cells themselves, triggering programmed cell death, halting cell division, and cutting off the blood supply tumors need to grow.

Wasser's systematic review of PSK in 2002 established this dual framework explicitly: "anticancer activity through T-cell activation, NK cell enhancement, macrophage activation, and direct antiproliferative effects on tumor cells."^[1]

Both mechanisms are documented in the most clinically studied compounds. The indirect immune pathway has extensive human clinical data behind it. The direct mechanisms are better documented in laboratory and animal studies, with clinical confirmation coming from the combination chemotherapy trials where both pathways reinforce each other.

For detail on each pathway, see:

• How Mushroom Sugars Activate Cancer-Fighting Immune Cells
• How Mushroom Polysaccharides Kill Cancer Cells: Four Distinct Mechanisms

The Immune Route: How Polysaccharides Recruit the Body's Defenses

The immune activation pathway starts at receptors called Dectin-1 and TLR4 on the surface of immune cells. These are pattern recognition receptors that normally detect pathogens. When a beta-glucan binds to them, the immune system reads it as a call to action.

What follows is a cascade. Macrophages shift from a maintenance state to an aggressive tumor-attacking state, then release cytokines, the chemical messenger molecules that summon and activate other immune cells. Dendritic cells mature and present tumor antigens to T cells, training them to recognize specific cancer markers. NK (natural killer) cells receive direct activation signals and begin seeking out and destroying tumor cells.

PSK drives this cascade toward what immunologists call Th1 polarization: a shift in the immune system's dominant response from tolerating abnormal cells to actively hunting them.^[4] In cancer, where tumor cells have evolved mechanisms to evade immune detection, this re-activation of the attack response is the core therapeutic rationale for using polysaccharides alongside conventional treatment.

Maitake D-Fraction added another dimension to this picture in a 2005 animal study. In tumor-bearing mice, Maitake D-Fraction combined with the chemotherapy agent mitomycin-C enhanced the anti-tumor activity of the chemotherapy while simultaneously reversing the immune suppression that chemotherapy causes.^[2] Mice receiving both agents had better tumor control and better preserved immune function than mice receiving chemotherapy alone.

This combination effect, polysaccharide as an immune protector that amplifies chemotherapy rather than conflicting with it, became one of the central practical rationales for the Japanese clinical programs.

The Direct Route: Attacking Cancer Cells Without Immune Intermediaries

The direct mechanisms are less discussed in consumer health writing, but they are documented across multiple species in peer-reviewed research.

Song and colleagues captured this in a single 2011 experiment. They applied a protein-bound polysaccharide from Phellinus linteus to SW480 colon cancer cells and observed three effects happening at the same time: tumor cell proliferation slowed, invasion into surrounding tissue decreased, and angiogenesis (the formation of new blood vessels that feed tumor growth) was inhibited. The mechanism ran through disruption of the Wnt/beta-catenin signaling pathway, a master regulator of cell growth that is overactive in many cancers.^[3]

This multi-mechanism attack profile matters for a specific reason. Cancer develops resistance to drugs that hit a single target; tumor cells find alternative growth routes around the blockade. A compound that simultaneously disrupts cell division, blocks tissue invasion, and cuts off blood supply faces a much higher evolutionary hurdle to resistance.

The four specific direct mechanisms documented in the literature, which are apoptosis (programmed cell death), cell cycle arrest, anti-angiogenesis, and immune-mediated cytotoxicity, are examined in depth in How Mushroom Polysaccharides Kill Cancer Cells: Four Distinct Mechanisms. The anti-angiogenesis pathway connects directly to Mushroom Anti-Angiogenic Compounds: Starving Tumors of Their Blood Supply.

From Lab to Clinic: The Three Approved Polysaccharide Cancer Drugs

Japan's approval of mushroom polysaccharides as cancer drugs was the outcome of multi-decade clinical trial programs, not a regulatory shortcut. Three compounds cleared that bar.

PSK (Krestin) is extracted from Turkey Tail mushroom (Trametes versicolor). It is approved in Japan for colorectal, gastric, and lung cancer as an adjuvant, a treatment added alongside chemotherapy rather than replacing it. Ma and colleagues' 2017 network meta-analysis combined data across multiple chemotherapy regimens and found that PSK improved both overall survival and disease-free survival in colorectal and gastric cancer patients, with an acceptable safety profile.^[5]

Lentinan is extracted from shiitake mushroom (Lentinula edodes) and approved in Japan and China. The clinical evidence base for lentinan is the broadest of the three drugs. Zhang and colleagues' 2019 review of 12 years of clinical data in China documented consistent benefit across nine cancer types including gastric, lung, colorectal, cervical, ovarian, and pancreatic cancers, in each case when lentinan was combined with chemotherapy.^[6] The most current synthesis, a 2024 systematic review and meta-analysis of injectable lentinan for gastric cancer, confirmed improved overall response rate, disease control rate, and quality of life compared to chemotherapy alone.^[8]

Schizophyllan (SPG) is extracted from Schizophyllum commune and approved in Japan for cervical cancer. English-language clinical literature on schizophyllan is limited compared to PSK and lentinan, but it rounds out the three approved drugs in this class.

Regulatory precision matters here. None of these are FDA-approved cancer drugs in the United States. In Japan, PSK is sold under the brand name Krestin; the regulatory category differs from the US prescription drug framework. Lentinan in Japan and China is an injectable drug requiring a physician prescription. The Turkey Tail and shiitake supplement products sold in the US are not the same pharmaceutical preparations used in the clinical trials, and treating them as equivalent would misrepresent what the evidence shows.

For the complete clinical evidence on each drug, approved indications, dosing, and trial data, see Polysaccharide-Based Anti-Cancer Drugs from Mushrooms. For lentinan's mechanism, clinical coverage, and cancer-type data in detail, see Lentinan: The Shiitake Compound Approved for Cancer Treatment in Japan.

Reading the Evidence: A Tier-by-Tier Look at What the Research Actually Shows

A 2023 systematic review by Narayanan and colleagues assessed all published clinical studies on medicinal mushroom supplements in cancer and mapped evidence quality by species.^[7]

Strongest clinical evidence: Turkey Tail (via PSK) and shiitake (via lentinan). Multiple randomized controlled trials and meta-analyses support survival benefit as adjuvants to chemotherapy. This is the same evidence tier that earns drug approval.

Moderate clinical evidence: Reishi and Maitake. Clinical studies exist but are smaller and less rigorous, or they show effects primarily on immune markers and quality of life rather than survival outcomes.

Limited clinical evidence: Most other species, including Lion's Mane, Chaga, and Cordyceps in the cancer context specifically. Laboratory and animal data exist; human clinical trial data is sparse.

AHCC (Active Hexose Correlated Compound), a standardized extract from Basidiomycete mushrooms, has clinical evidence specifically for HPV clearance and quality of life improvement in cancer patients. That is a distinct category from the survival data for PSK and lentinan.

This hierarchy is not a verdict on which mushrooms are useful or useless. It reflects decades of clinical research investment. PSK and lentinan had national clinical programs behind them in Japan. Most other species have not had equivalent investment in controlled human trials. The laboratory mechanisms documented for other species are real; the gap between a cell culture result and a randomized controlled trial showing survival benefit is large, and for most species, that gap has not been closed.

Understanding which tier any given finding belongs to is the only honest way to interpret claims in this space.

What Population Data Adds to the Mechanistic Picture

Epidemiological studies reviewed in Mushroom Consumption and Cancer Risk Reduction: Meta-Analysis of Population Studies found associations between regular mushroom consumption and reduced cancer incidence in population cohorts. The polysaccharide mechanisms described in this article offer a plausible biological explanation for those associations, though the concentrations of active polysaccharides in dietary mushrooms are much lower than in clinical drug preparations.

The population data is context. The clinical trial data for PSK and lentinan is the substance.

The Bottom Line

The clinical evidence on mushroom polysaccharides and cancer is both stronger than most people realize and narrower than the supplement industry suggests. PSK from Turkey Tail and lentinan from shiitake have the most robust support: multiple randomized controlled trials, meta-analyses, and over four decades of clinical use in Japan as approved cancer drugs. Their anti-cancer activity runs through two documented pathways, immune activation and direct tumor cell killing, both grounded in mechanistic and clinical research. Most other mushroom species have promising laboratory data and limited human clinical evidence. The gap between those two things is substantial, and in this medical context, it matters.

Frequently Asked Questions

Can mushroom polysaccharides kill cancer cells?

Yes, mushroom polysaccharides can kill cancer cells through both direct and indirect mechanisms. Directly, they trigger apoptosis (programmed cell death), arrest cell division at growth checkpoints, and inhibit the blood vessel formation tumors need to expand. Indirectly, they activate NK cells, T cells, macrophages, and dendritic cells to recognize and attack tumors. The direct mechanisms are primarily documented in laboratory studies; the immune mechanisms are supported by human clinical trials, including meta-analyses of randomized controlled trials for PSK and lentinan.

Which mushroom polysaccharides have the most evidence against cancer?

PSK from Turkey Tail mushroom and lentinan from shiitake have the strongest clinical evidence. Both are approved prescription cancer drugs in Japan, backed by randomized controlled trials and meta-analyses showing improved survival versus chemotherapy alone. A 2023 systematic review by oncology researchers ranked them as the top two medicinal mushrooms for cancer evidence. Reishi and Maitake have moderate clinical evidence. Most other species have laboratory data without equivalent human trial support.

How do beta-glucans help fight cancer?

Beta-glucans, the polysaccharides in mushroom cell walls, bind to pattern recognition receptors called Dectin-1 and TLR4 on immune cells, triggering a cascade that activates macrophages, NK cells, dendritic cells, and T cells to attack tumors. Beta-glucans also act directly on cancer cells by activating apoptosis pathways, arresting cell division at growth checkpoints, and disrupting signaling pathways like Wnt/beta-catenin that cancer cells rely on for growth and invasion.

Are mushroom polysaccharides used in cancer treatment?

Yes, in Japan and China. PSK (sold as Krestin) is approved in Japan for colorectal, gastric, and lung cancer as an add-on to chemotherapy. Lentinan is approved in Japan and China for gastric cancer and several additional cancer types. Neither is FDA-approved in the United States. Supplement products sold in the US under Turkey Tail or shiitake labels are not the same pharmaceutical preparations used in the clinical trials, and the two should not be equated.

What is the difference between PSK and lentinan?

PSK (polysaccharide-K) comes from Turkey Tail mushroom; lentinan comes from shiitake. PSK is a protein-bound beta-glucan; lentinan is a pure beta-1,3/1,6-glucan. Their approved indications differ: PSK is approved in Japan for colorectal, gastric, and lung cancers; lentinan is approved in Japan and China with clinical benefit documented across nine cancer types including gastric, lung, cervical, and ovarian. In Japan, lentinan is an injectable requiring a physician prescription; PSK is available under a different regulatory category. Both activate immune cells against tumors but through partially distinct receptor pathways, and PSK also has documented direct anti-proliferative effects on tumor cells.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2RTHM-00161·Kodama, Noriko et al. (2005). “Maitake D-Fraction enhances antitumor effects and reduces immunosuppression by mitomycin-C in tumor-bearing mice..” Nutrition (Burbank.Study breakdown →PubMed →↩
3. 3RTHM-00437·Song, Kyoung-Sub et al. (2011). “Protein-bound polysaccharide from Phellinus linteus inhibits tumor growth, invasion, and angiogenesis and alters Wnt/β-catenin in SW480 human colon cancer cells..” BMC cancer.Study breakdown →PubMed →↩
4. 4RTHM-00475·Maehara, Yoshihiko et al. (2012). “Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN(®)): review of development and future perspectives..” Surgery today.Study breakdown →PubMed →↩
5. 5RTHM-00895·Ma, Yan et al. (2017). “Can polysaccharide K improve therapeutic efficacy and safety in gastrointestinal cancer? a systematic review and network meta-analysis..” Oncotarget.Study breakdown →PubMed →↩
6. 6RTHM-01153·Zhang, Meng et al. (2019). “Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China..” Progress in molecular biology and translational science.Study breakdown →PubMed →↩
7. 7RTHM-01760·Narayanan, Santhosshi et al. (2023). “Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies..” Current oncology reports.Study breakdown →PubMed →↩
8. 8RTHM-02015·Wang, Yixuan et al. (2024). “Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer..” Phytomedicine : international journal of phytotherapy and phytopharmacology.Study breakdown →PubMed →↩